S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property
Literal federal measure citations: S. 1096
Source-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- Not reported
- Expenses
- $2,110,000.00
- Registrant
- ABBVIE, INC.
- Client
- ABBVIE INC.
- Filing UUID
- dfe0964f-e3fe-4fd1-8024-f3122cb1639a
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
S. 864, HELP Copays Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program
Literal federal measure citations: S. 864
Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program and smoothing out-of-pocket costs for patients Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment
Literal federal measure citations: H.R. 5376
H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program
Literal federal measure citations: H.R. 1328, H.R. 1990, H.R. 1
Issues related to antitrust and competition policy
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.